Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

High Rate of Virological Response to Peginterferon alpha-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C

(2012) High Rate of Virological Response to Peginterferon alpha-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. Iranian Red Crescent Medical Journal. pp. 466-469. ISSN 2074-1804

[img] Text
High rate of virological response to peginterferon $α$-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C.pdf

Download (150kB)

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Background: Hepatitis C is a major reason of morbidity and mortality among hemophilia patients. Although combination therapy with peginterferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed. Objectives: In this study, efficacy and tolerability of combination therapy with peginterferon alpha-2a-ribavirin was investigated among hemophilia HCV infected patients. Patients and Materials: In a quasi-experimental, 45 naive hemophilia patients with chronic HCV received 180 mg of pegylated interferon (Pegasys) by subcutaneous injection weekly plus an oral dose of 800-1200 mu g ribavirin daily according to body weight. The treatment continued 48 weeks in patients with genotype one and 24 weeks in those with genotype 3. Sustained virological response (SVR) was considered as efficacy of treatment. Result: Forty three patients (95.6) reached to end of treatment response (ETR); only two (4.4) patients did not respond and were discontinued from treatment. None of 43 patients relapsed. SVR obtained in 43 of 45 patients (95.6), in multivariate logistic regression model, third month's treatment WBC (WBC > 2000) remained the only significant predictor of SVR. Regimen dose reduced in three patients; two of those because of ALT increasing and other one for his retinal bleeding. In repeated measurement analysis, alanine aminotransferase (ALT) and hemoglobin (Hb) decreased significantly during treatment, but reduction of platelet (PLT) was not significant. Conclusions: Results show high efficacy and safety of combination therapy of Peg-IFN-alpha 2a plus ribavirin among hemophiliacs with chronic hepatitis C.

Item Type: Article
Keywords: Hepatitis C Hemophilia A Hemophilia B Peginterferon alfa-2a Ribavirin Iran pegylated interferon bleeding disorders single-center ribavirin alpha-2a hcv infection therapy efficacy safety General & Internal Medicine
Divisions:
Page Range: pp. 466-469
Journal or Publication Title: Iranian Red Crescent Medical Journal
Journal Index: ISI
Volume: 14
Number: 8
ISSN: 2074-1804
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/6264

Actions (login required)

View Item View Item